TERN Terns Corp: Market Value

Serving as confirmation of the market valuation, this Terns Pharmaceuticals (TERN) price chart demonstrates the dynamics of a company developing therapies for gastrointestinal organs. The business operates amidst fierce competition with industry behemoths in the race for regulatory approval. Meanwhile, the market capitalization stands at 5.94. Operations rely on accelerating tests for new NASH drugs, remaining insensitive to GDP but dependent on venture financing.

TERN Terns Pharmaceuticals, Inc.: Market Capitalization in the range 07/04/2022 - 05/16/2026

Comprehensive metric breakdowns and analytics for Terns Corp (TERN)

- current price and projected stock value:

Stock Price Terns Pharmaceuticals, Inc.|TERN - Average Forecast Price

- company stock capitalization data:

Market Value Terns Corp|TERN - Value Adjusted for Debt and Cash

- book value of equity indicators:

Net Assets per Single Share Terns Pharmaceuticals|TERN - Accounting Capitalization|Market Value to Book Value Ratio ternspharma.com|TERN - Total Asset Value of Company

- debt and solvency information:

- business earnings and investment ratios data:

TERN - Net Profit|Future Profit Terns Pharmaceuticals|TERN - Company Value to Net Income|Forward P/E Multiple Terns Pharmaceuticals Inc|TERN - Price to Net Income Growth Ratio|EV/EBITDA Multiple Terns Corp|TERN - Operating income before deduction of amortization|Net earnings per share for the last 12 months Terns Pharmaceuticals|TERN - Earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months ternspharma.com|TERN - Net earnings per one share growth for the current year|Earnings growth forecast for next year Terns Pharmaceuticals

Fundamental company analysis:TERN (Terns Pharmaceuticals, Inc.)

Market capitalization measures the aggregate value of all a company's shares, determining the current business valuation by multiplying the closing price by the total number of securities. The market capitalization dynamics of Terns Pharmaceuticals (TERN) reflect market expectations for the success of its oral GLP-1 analogue, where the asset's value correlates directly with clinical trial results and the available cash runway for R&D.

Key competitors